Presented by Heather Landau, MD, who is a hematologist-oncologist and the Director of the Amyloid Program at Memorial Sloan Kettering (MSK) Cancer Center; New York, NY.

18 october 19h30CET 13h30ET

Speakers:

Michelle Kittleson
Director of Education in Heart Failure and Transplantation, Professor of Medicine, Smidt Heart Institute , Cedars-Sinai, USA
Presentation: Amyloidosis: Red Flags and Clinical Clues

Benjamin Essayagh
Division of Cardiovascular Disease, Mayo Clinic, Minnesota, USA & Cannes Hospital, France
Presentation: The Role of Imaging Studies in the Diagnosis of Cardiac Amyloidosis

Frederick Ruberg
Associate Chief, Academic Affairs, Section of Cardiovascular Medicine
Associate Professor of Medicine and Radiology, Boston University School of Medicine, USA
Presentation: The Diagnostic Algorithm: The Role of the Monoclonal Light Chain Screen, Genetic Testing, and Biopsies

Mathew Maurer
Columbia University Irving Medical Center, New York Presbyterian Hospital, USA
Presentation: Treatment of Transthyretin Amyloidosis: Current Therapies and Future Promise

Moderators:

Michelle Kittleson
Director of Education in Heart Failure and Transplantation, Professor of Medicine, Smidt Heart Institute , Cedars-Sinai
Presentation: Amyloidosis: Red Flags and Clinical Clues

Alexandru Mischie, M.D., PhD, FAHA, FESC
Head of Interventional Cardiology Department Centre Hospitalier Montlucon, France
Chair of the Tele-Cardiology Working Group ISfTeH

Kavita Sharma, Director of Heart Failure and Cardiac Transplantation, presents a patient case on amyloidosis. She provides an explanation of amyloidosis along with new treatment and therapy options available at Johns Hopkins. She discusses the patient's journey and how the severity of his case led to a combined heart and kidney transplant.

Ronald Witteles, MD, Stanford University, Stanford, CA, discusses challenges that remain in the diagnosis of transthyretin (ATTR) amyloidosis. Diagnosis of this disease can be straightforward: from an initial suspicion, a monoclonal paraprotein assessment to rule out light chain (AL) amyloidosis and a technetium scintigraphy are conducted, and additional genetic testing can determine the exact mutation responsible for the disease. However, raising the initial suspicion poses a challenge, as other conditions that co-exist with ATTR amyloidosis, such as carpal tunnel syndrome and lumbar spinal stenosis, are often overlooked by cardiologists. Seeing that testing is non-invasive, accurate, and that treatment options can greatly reduce disease burden, it is important to inform doctors and establish basic findings and demographics which should trigger an evaluation for ATTR amyloidosis. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Dawn describes her experience as a hereditary amyloidosis caregiver and patient, experiencing the onset of symptoms, her treatment journey, and advice for others living with hATTR amyloidosis.

In this video, Kiavasch Farid, MD, Heidelberg University Hospital, Heidelberg, Germany, briefly comments on the need to monitor patients with monoclonal gammopathy of undetermined significance (MGUS) to allow for early detection of progression to light chain (AL) amyloidosis. Dr Farid emphasizes the importance of yearly screening, including checking serum parameters such as NT-ProBNP and alkaline phosphatase, as well as monitoring for albuminuria, to help detect disease progression. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Early diagnosis can make all the difference for multiple myeloma and AL amyloidosis patients, but delays are common. In this webinar, Dr. Nadine Abdallah will share findings from her HealthTree research, “AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis.” She’ll discuss how the study was conducted, key results, and why they matter to patients. Learn how you can help improve future research by participating in studies and surveys. A Patient Navigator, from HealthTree, will be available at the end of the webinar to answer any questions you have about HealthTree Cure Hub and how you can power lifesaving research. Don’t miss this important discussion!